From control to eradication of malaria: the end of being stuck in second gear?

Asian Pacific Journal of Tropical Medicine

Volumn 3, Issue 5, 2010, Pages 412-420

  Khadjavi, Amina ^a   Giribaldi, Giuliana ^a   Prato, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Anopheles mosquito; Antimalarial drugs; Hemozoin; Malaria; Matrix metalloproteinases; Plasmodium falciparum; Vaccine; Vector control

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; 8 AMINOQUINOLINE DERIVATIVE; AMINOALCOHOL; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; CIRCUMSPOROZOITE PROTEIN; CLINDAMYCIN; DOXYCYCLINE; FANSIDAR; FOLIC ACID ANTAGONIST; GELATINASE B; HALOFANTRINE; HEMOGLOBIN; HEMOZOIN; INTERLEUKIN 1BETA; MALARIA VACCINE; MEFLOQUINE; PRIMAQUINE; PYRIMETHAMINE; QUININE; TETRACYCLINE; THROMBOSPONDIN; THROMBOSPONDIN RELATED ANONYMOUS PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOPHELES; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BED NET; CARDIOTOXICITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE TRANSMISSION; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG STRUCTURE; ERYTHROCYTE; ERYTHROCYTE METABOLISM; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; HYPOGLYCEMIA; INFECTION CONTROL; INSECT BITE; INSECTICIDE RESISTANCE; INSOMNIA; LIVER; MALARIA; MALARIA FALCIPARUM; MENTAL DISEASE; MEROZOITE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; SPOROZOITE; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VECTOR CONTROL;

EID: 77953250190     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(10)60101-0     Document Type: Article

References (88)

1. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008, 5:e38.
2. Greenwood BM Control to elimination: implications for malaria research. Trends Parasitol 2008, 24:449-454.
3. Spielman A, Kitron U, Pollack RJ Time limitation and the role of research in the worldwide attempt to eradicate malaria. J Med Entomol 1993, 30:6-19.
4. Hayton K, Su XZ Drug resistance and genetic mapping in Plasmodium falciparum. Curr Genet 2008, 54:223-239.
5. Roberts L, Enserink M Did they really say eradication?. Science 2007, 318:1544-1545.
6. Daneshvar C, Davis TM, Cox-Singh J, Rafa'ee MZ, Zakaria SK, Divis PC, et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009, 49:852-860.
7. Campbell CC Malaria: an emerging and re-emerging global plague. FEMS Immunol Med Microbiol 1997, 18:325-331.
8. Ejigiri I, Sinnis P Plasmodium sporozoite-host interactions from the dermis to the hepatocyte. Curr Opin Microbiol 2009, 12:401-407.
9. Amino R, Giovannini D, Thiberge S, Gueirard P, Boisson B, Dubremetz JF, et al. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe 2008, 3:88-96.
10. Rathore D, Hrstka SC, Sacci JB, De la Vega P, Linhardt RJ, Kumar S Molecular mechanism of host specificity in Plasmodium falciparum infection: role of circumsporozoite protein. J Biol Chem 2003, 278:40905-40910.
11. Müller HM, Scarselli E, Crisanti A Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum in parasite-host cell interactions. Parassitologia 1993, 35(Suppl):69-72.
12. Prudêncio M, Rodriguez A, Mota MM The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol 2006, 4:849-856.
13. Mikolajczak SA, Jacobs-Lorena V, MacKellar DC, Camargo N, Kappe SH L-FABP is a critical host factor for successful malaria liver stage development. Int J Parasitol 2007, 37:483-489.
14. Galinski MR, Barnwell JW Plasmodium vivax: who cares?. Malar J 2008, 7:S9.
15. Kariuki MM, Li X, Yamodo I, Chishti AH, Oh SS Two Plasmodium falciparum merozoite proteins binding to erythrocyte band 3 form a direct complex. Biochem Biophys Res Commun 2005, 338:1690-1695.
16. Mitchell GH, Thomas AW, Margos G, Dluzewski AR, Bannister LH Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun 2004, 72:154-158.
17. Baum J, Maier AG, Good RT, Simpson KM, Cowman AF Invasion by P. falciparum merozoites suggests a hierarchy of molecular interactions. PLoS Pathog 2005, 1:e37.
18. Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993, 261:1182-1184.
19. Bannister LH, Hopkins JM, Fowler RE, Krishna S, Mitchell GH A brief illustrated guide to the ultrastructure of Plasmodium falciparum asexual blood stages. Parasitol Today 2000, 16:427-433.
20. Rosenthal PJ, Meshnick SR Hemoglobin catabolism and iron utilization by malaria parasites. Mol Biochem Parasitol 1996, 83:131-139.
21. Arese P, Schwarzer E Malarial pigment (haemozoin): a very active 'inert' substance. Ann Trop Med Parasitol 1997, 91:501-516.
22. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, et al. UK malaria treatment guidelines. J Infect 2007, 54:111-121.
23. Scorza T, Magez S, Brys L, De Baetselier P Hemozoin is a key factor in the induction of malaria-associated immunosuppression. Parasite Immunol 1999, 21:545-554.
24. Schwarzer E, Turrini F, Ulliers D, Giribaldi G, Ginsburg H, Arese P Impairment of macrophage functions after ingestion of plasmodium falciparum-infected erythrocytes or isolated malarial pigment. J Exp Med 1992, 176:1033-1041.
25. Fiori PL, Rappelli P, Mirkarimi SN, Ginsburg H, Cappuccinelli P, Turrini F Reduced microbicidal and anti-tumour activities of human monocytes after ingestion of Plasmodium falciparum infected red blood cells. Parasite Immunol 1993, 15:647-655.
26. Giribaldi G, Ulliers D, Schwarzer E, Roberts I, Piacibello W, Arese P Hemozoin- and 4-hydroxynonenal-mediated inhibition of erythropoiesis. Possible role in malarial dyserythropoiesis and anemia. Haematologica 2004, 89:492-493.
27. Pichyangkul S, Saengkrai P, Webster HK Plasmodium falciparum pigment induce monocytes to release high levels of tumor necrosis factor-alpha and interleukin-1beta. Am J Trop Med Hyg 1994, 51:430-435.
28. Sherry BA, Alava G, Tracey KJ, Martiney J, Cerami A, Slater AF Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. J Inflamm 1995, 45:85-96.
29. Clark IA, Rockett KA The cytokine theory of human cerebral malaria. Parasitol Today 1994, 10:410-412.
30. Prato M, Giribaldi G, Polimeni M, Gallo V, Arese P Phagocytosis of hemozoin enhances matrix metalloproteinase-9 activity and TNF-alpha production in human monocytes: role of matrix metalloproteinases in the pathogenesis of falciparum malaria. J Immunol 2005, 175:6436-6442.
31. Prato M, Gallo V, Giribaldi G, Arese P Phagocytosis of haemozoin (malarial pigment) enhances metalloproteinase-9 activity in human adherent monocytes: role of IL-1beta and 15-HETE. Malar J 2008, 7:157.
32. Van den Steen PE, Van Aelst I, Starckx S, Maskos K, Opdenakker G, Pagenstecher A Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria. Lab Invest 2006, 86:873-888.
33. Prato M, Giribaldi G, Arese P Hemozoin triggers tumor necrosis factor alpha-mediated release of lysozyme by human adherent monocytes: new evidences on leukocyte degranulation in P. falciparum malaria. Asian Pac J Trop Med 2009, 2:35-40.
34. Prato M, Gallo V, Arese P Higher production of tumor necrosis factor alpha in hemozoin-fed human adherent monocytes is dependent on lipidic component of malarial pigment: new evidences on cytokine regulation in Plasmodium falciparum malaria. Asian Pac J Trop Med 2010, 3:85-89.
35. Geurts N, Martens E, Van Aelst I, Proost P, Opdenakker G, Van den Steen PE Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry 2008, 47:2689-2699.
36. O'Neill PM, Ward SA, Berry NG, Jeyadevan JP, Biagini GA, Asadollaly E, et al. A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr Top Med Chem 2006, 6:479-507.
37. Brocks DR, Mehvar R Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 2003, 42:1359-1382.
38. Yuthavong Y, Kamchonwongpaisan S, Leartsakulpanich U, Chitnumsub P Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol 2006, 1:113-125.
39. Vale N, Moreira R, Gomes P Primaquine revisited six decades after its discovery. Eur J Med Chem 2009, 44:937-953.
40. Mercer AE The role of bioactivation in the pharmacology and toxicology of the artemisinin-based antimalarials. Curr Opin Drug Discov Devel 2009, 12:125-132.
41. Whitty CJ, Chandler C, Ansah E, Leslie T, Staedke SG Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J 2008, 7:S7.
42. Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1998, 92:201-206.
43. Stanway RR, Witt T, Zobiak B, Aepfelbacher M, Heussler VT GFP-targeting allows visualization of the apicoplast throughout the life cycle of live malaria parasites. Biol Cell 2009, 101:415-430.
44. Baird JK, Schwartz E, Hoffman SL Prevention and treatment of vivax malaria. Curr Infect Dis Rep 2007, 9:39-46.
45. Sá JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, et al. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci U S A 2009, 106:18883-18889.
46. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003, 47:2418-2423.
47. Hankins EG, Warhurst DC, Sibley CH Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. Mol Biochem Parasitol 2001, 117:91-102.
48. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994, 88:218-219.
49. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
50. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-467.
51. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010, 8:272-280.
52. Legrand E First case of emergence of atovaquone resistance in Plasmodium falciparum during second-line atovaquone-proguanil treatment in South America. Antimicrob Agents Chemother 2007, 51:2280-2281.
53. Schlitzer M Antimalarial drugs - what is in use and what is in the pipeline. Arch Pharm (Weinheim) 2008, 341:149-163.
54. D'alessandro U Progress in the development of piperaquine combinations for the treatment of malaria. Curr Opin Infect Dis 2009, 22:588-592.
55. Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop 2008, 105:222-228.
56. Nasveld P, Kitchener S Treatment of acute vivax malaria with tafenoquine. Trans R Soc Trop Med Hyg 2005, 99:2-5.
57. Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, et al. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One 2009, 4:e6682.
58. Borrmann S, Adegnika AA, Moussavou F, Oyakhirome S, Esser G, Matsiegui PB, et al. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2005, 49:3749-3754.
59. Heppner DG, Walsh DS, Uthaimongkol N, Tang DB, Tulyayon S, Permpanich B, et al. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of Plasmodium vivax malaria in Western Thailand. Am J Trop Med Hyg 2005, 73:842-849.
60. Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, Walsh DS, Knirsch C, et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg 2006, 74:401-406.
61. Krudsood S, Buchachart K, Chalermrut K, Charusabha C, Treeprasertsuk S, Haoharn O, et al. A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug resistant falciparum malaria. Southeast Asian J Trop Med Public Health 2002, 33:525-531.
62. Sykes A, Hendriksen I, Mtove G, Mandea V, Mrema H, Rutta B, et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis 2009, 15(49):1195-1201.
63. Yeramian P, Meshnick SR, Krudsood S, Chalermrut K, Silachamroon U, Tangpukdee N, et al. Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. J Infect Dis 2005, 192:319-322.
64. Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, Hadi CM, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007, 2:e6.
65. Dubar F, Khalife J, Brocard J, Dive D, Biot C Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action. Molecules 2008, 13:2900-2907.
66. Davis CB, Bambal R, Moorthy GS, Hugger E, Xiang H, Park BK, et al. Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials. J Pharm Sci 2009, 98:362-377.
67. Salom-Roig XJ, Hamzé A, Calas M, Vial HJ Dual molecules as new antimalarials. Comb Chem High Throughput Screen 2005, 8:49-62.
68. Nzila A, Okombo J, Becker RP, Chilengi R, Lang T, Niehues T Anticancer agents against malaria: time to revisit?. Trends Parasitol 2010, 26:125-129.
69. Guyatt HL, Corlett SK, Robinson TP, Ochola SA, Snow RW Malaria prevention in highland Kenya: indoor residual house-spraying vs. insecticide-treated bednets. Trop Med Int Health 2002, 7:298-303.
70. Davies TE, O'Reilly AO, Field LM, Wallace B, Williamson MS Knockdown resistance to DDT and pyrethroids: from target-site mutations to molecular modelling. Pest Manag Sci 2008, 64:1126-1130.
71. Hargreaves K, Koekemoer LL, Brooke BD, Hunt RH, Mthembu J, Coetzee M Anopheles funestus resistant to pyrethroid insecticides in South Africa. Med Vet Entomol 2000, 14:181-189.
72. Girod R, Orlandi-Pradines E, Rogier C, Pages F Malaria transmission and insecticide resistance of Anopheles gambiae (Diptera: Culicidae) in the French military camp of Port-Bouët, Abidjan (Côte d'Ivoire): implications for vector control. J Med Entomol 2006, 43:1082-1087.
73. Williamson MS, Martinez-Torres D, Hick CA, Devonshire AL Identification of mutations in the housefly para-type sodium channel gene associated with knockdown resistance (kdr) to pyrethroid insecticides. Mol Gen Genet 1996, 252:51-60.
74. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008, 118:1266-1276.
75. Targett GA, Greenwood BM Malaria vaccines and their potential role in the elimination of malaria. Malar J 2008, 7:S10.
76. Stevenson MM, Zavala F Immunology of malaria infections - implications for the design and development of malaria vaccines. Parasite Immunol 2006, 28:1-60.
77. Targett GA Malaria vaccines 1985-2005: a full circle?. Trends Parasitol 2005, 21:499-503.
78. Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007, 75:3758-3768.
79. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997, 336:86-91.
80. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358:1927-1934.
81. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002, 185:820-827.
82. Babaeekho L, Zakeri S, Djadid ND Genetic mapping of the duffy binding protein (DBP) ligand domain of Plasmodium vivax from unstable malaria region in the Middle East. Am J Trop Med Hyg 2009, 80:112-118.
83. Gill J, Chitnis CE, Sharma A Structural insights into chondroitin sulphate A binding Duffy-binding-like domains from Plasmodium falciparum: implications for intervention strategies against placental malaria. Malar J 2009, 8:67.
84. Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 1998, 4:772-782.
85. Pradel G Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategies. Parasitology 2007, 134:1911-1929.
86. Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J 2007, 6:107.
87. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23:3131-3138.
88. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008, 3:e2636.